deltatrials
Unknown PHASE2 NCT00026442

Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

A Pilot Trial Of Two Different Doses Of Capecitabine (XELODA) In Patients With Advanced And/Or Metastatic Breast Cancer

Sponsor: Pharmatech Oncology

Conditions Breast Cancer
Interventions capecitabine
Updated 6 times since 2017 Last updated: Dec 17, 2013 Started: Nov 30, 2001

This PHASE2 trial investigates Breast Cancer and is currently ongoing. Pharmatech Oncology leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pharmatech Oncology
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Baltimore, United States
  • • Charleston, United States
  • • Collierville, United States
  • • Colorado Springs, United States
  • • Lancaster, United States
  • • Logan, United States
  • • Orange, United States
  • • Port Saint Lucie, United States
  • • Saint Augustine, United States
  • • West Covina, United States